The Conversation (0)
Stem Cell Therapeutics (TSXV:SSS) announced that its merger with Trillium Therapeutics Inc has been completed with the latter’s shareholders voting strongly in support of the move. The company also issued 2,560,197 stock options to directors, officers and employees with an exercise price of $0.25 and a 10-year term.
Stem Cell Therapeutics announced that its merger with Trillium Therapeutics Inc has been completed with the latter’s shareholders voting strongly in support of the move. The company also issued 2,560,197 stock options to directors, officers and employees with an exercise price of $0.25 and a 10-year term.
As quoted in the press release:
The company also announced the issuance of 2,560,197 stock options under its stock option plan to directors, officers and employees reflecting the addition of the executives and staff of the merged entity. The options have an exercise price of $0.25 and a term of ten years. The issuance of stock options is subject to acceptance by the TSX Venture exchange.
Click here to read the full Stem Cell Therapeutics press release.
